TrueRelief

What TrueRelief does

TrueRelief is a privately held medical device company headquartered in Santa Monica, California, that develops and commercializes an FDA 510(k)-cleared, non-invasive neuromodulation device for pain management. The device delivers proprietary 20,000 Hz high-frequency electrical stimulation combined with pulsed direct current through dynamically directed stainless steel probes, and is cleared for use in both chronic intractable pain and post-surgical acute pain indications. The company has built a substantial IP position around this architecture, holding 26 registered patents with approximately 24 additional applications pending. Clinical evidence supporting the platform includes peer-reviewed studies conducted with the Feinstein Institutes for Medical Research (Northwell Health), published in Bioelectronic Medicine, and a cesarean section trial with Ohio State University Wexner Medical Center published in JAMA Network Open.

The business operates a professional-channel hardware sales model, distributing the device exclusively through healthcare practitioners including hospitals, ambulatory surgical centers, and physical therapy practices. Pricing is quote-based and structured around multi-year contracts, indicating a direct enterprise field sales motion rather than consumer or retail distribution. The company also operates a sub-brand, TrueRelief Equine, which extends the underlying stimulation technology into the animal health market. End-user adoption disclosed publicly is limited to two named accounts: a physical therapy practice in Charlotte, North Carolina, and a surgical practice in Beverly Hills, California.

TrueRelief employs between 11 and 50 people and has assembled an advisory board that includes former Johnson & Johnson executives and a Duke-affiliated spine surgeon. Capital inflows disclosed consist of a single $244,000 federal grant awarded under the HHS/Treasury/NIH Therapeutic Discovery Project Program; no institutional venture funding has been reported. The company claims a 99% treatment effectiveness rate across more than 1,000 patients based on its clinical dataset.

Name

TrueRelief

Legal name

TrueRelief, LLC

Website

https://truerelief.com

Company type

Private

Operating status

Operating

Headcount range

11–50 employees

Short description

TrueRelief is a private medical device company that sells an FDA-cleared, non-invasive neuromodulation device using proprietary high-frequency electrical stimulation for chronic and post-surgical pain, distributed exclusively through hospitals, surgical centers, and physical therapy practices, with an equine animal-health sub-brand.

Ownership category

akta.pro rank

Product category

Pain Management Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS) (HLAHAEAK)

akta.pro secondary industry

Rehabilitation & Physical Therapy Devices (Laser, Hydrotherapy, TENS) (HLAMAFAK)

Keywords

• Neuromodulation pain management
• Non-opioid pain relief
• Medical device electrotherapy
• Post-surgical pain management
• Chronic pain treatment

Headquarters

HQ city

Santa Monica

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Medical Device Sales: Sale of TrueRelief neuromodulation devices and treatments to healthcare professionals and clinical settings including hospitals, surgical centers, and physical therapy practices

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

TrueRelief manufactures and sells an FDA-cleared, non-invasive neuromodulation device that delivers 20,000 Hz high-frequency pulsed direct current through dynamically directed stainless steel tipped probes to manage post-surgical acute pain and chronic intractable pain as a non-opioid alternative. The device is sold exclusively to healthcare professionals—hospitals, surgical centers, and physical therapy practices—who administer treatments to patients. A separate equine-use device variant extends the platform into veterinary applications.

Product overview

TrueRelief offers a portfolio centered on its core TrueRelief Device, a non-opioid, non-invasive neuromodulation platform for pain management. The device utilizes proprietary high-frequency electrical stimulation technology (20,000 Hz with pulsed direct current) and unique dynamically directed stainless steel tipped probes administered by trained clinicians. The portfolio includes a dedicated equine use device variant for animal health. The technology is FDA-cleared for relief of chronic intractable pain and as an adjunctive treatment for post-surgical and post-traumatic acute pain, and has been validated through peer-reviewed clinical studies including research published in Bioelectronic Medicine and JAMA Network Open.

Differentiator

Problem solved

Functional benefit

Brands

• TrueRelief Animal Health: A dedicated site and potentially separate device for veterinary/animal pain management applications.

Products and services

• TrueRelief Device Non-opioid, non-invasive neuromodulation device using 20,000 Hz high-frequency pulsed direct current through dynamically directed stainless steel tipped probes to manage chronic intractable pain and post-surgical/post-traumatic acute pain as an alternative to opioids. Sold exclusively through healthcare professionals—hospitals, surgical centers, and physical therapy practices—who administer nurse- or technician-delivered treatments.
• TrueRelief Equine Use Device A version of the TrueRelief neuromodulation device designed for equine (horse) use, applying the same proprietary 20,000 Hz high-frequency electrical stimulation technology to veterinary pain management applications.

Quantifiable outcome

• 47% reduction in opioid usage in post-operative patients
• +4 more outcomes

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered core.

• Feinstein Institutes for Medical Research (Northwell Health)coreStrategic or Co-development PartnerCollaborative research partnership for TrueRelief's Mechanism of Action study; two-year peer-reviewed study published in Bioelectronic Medicine in 2022; Dr. Timir Datta-Chaudhuri heads the Bioelectronics Laboratory at the Institute of Bioelectronic Medicine
• The Ohio State University Wexner Medical CentercoreStrategic or Co-development PartnerSham-controlled clinical trial for TrueRelief following cesarean section surgery, published by JAMA Network Open, finding patients consumed 47% less opioids than sham treatment group; Dr. Kara Rood served as principal investigator

Scale indicators9 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• SPR Therapeutics: SPR Therapeutics develops the Sprint peripheral nerve stimulation (PNS) system, a minimally invasive neurostimulation treatment for chronic and post-surgical pain. Targets overlapping surgical and chronic pain indications with strong clinical evidence.
• Calmare Therapeutics: Calmare manufactures the Scrambler therapy device, a non-invasive, non-pharmacologic neurostimulation device for chronic and neuropathic pain. It is the closest direct competitor to TrueRelief in mechanism and clinical positioning.
• Nevro Corp: Nevro markets the Senza and HFX spinal cord stimulation systems for chronic pain, with peer-reviewed evidence for non-opioid pain control. Directly competes in the neuromodulation-for-pain category with FDA-cleared devices.

Emerging players

• BioElectronics Corporation: BioElectronics makes ActiPatch and RecoveryRx pulsed electromagnetic/electrotherapy devices for pain and post-surgical recovery. A smaller peer in the non-invasive, non-opioid consumer/clinical pain management category.
• NeuroMetrix: NeuroMetrix developed the Quell wearable TENS device for chronic pain, FDA-cleared and over-the-counter. Similar non-opioid neuromodulation positioning but consumer/home-use rather than clinician-administered.
• Zynex Medical: Zynex manufactures and sells TENS/EMS devices, including the NexWave and M-Wave lines for pain management. A smaller neuromodulation player competing in electrotherapy for pain with predominantly OTC channels.

Broad incumbents

• DJO / Enovis (Chattanooga, Compex): Enovis (formerly DJO) sells Chattanooga electrotherapy devices and Compex muscle stimulation units widely used in physical therapy clinics. Direct competition in the rehabilitation and pain management channel.
• Medtronic (Intellis / Vanta): Medtronic offers Intellis and Vanta neurostimulators for chronic pain and emerging post-surgical indications. A broad incumbent with hospital sales coverage far exceeding TrueRelief's footprint.
• Abbott (Proclaim XR / Eterna): Abbott sells Proclaim dorsal root ganglion and spinal cord stimulation systems through its Neuromodulation division. A large incumbent that competes for the same chronic pain and post-surgical pain patients with substantially more resources.
• Boston Scientific (WaveWriter): Boston Scientific's WaveWriter and Precision spinal cord stimulation systems serve the chronic pain and opioid-sparing markets. A direct competitor among large medtech neuromodulation players.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TrueRelief